Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11)

SUSAN J. ZUNINO¹, DAVID H. STORMS¹ and JONATHAN M. DUCORE²

¹United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, 430 West Health Sciences Drive, University of California, Davis, CA 95616; ²Department of Pediatrics, Section of Hematology/Oncology, University of California School of Medicine, 2516 Stockton Blvd., Sacramento, CA 95817, USA

Received July 9, 2010; Accepted August 20, 2010

DOI: 10.3892/ijo_00000782

Abstract. Parthenolide, the principal bio-active component of the herb feverfew (Tanacetum parthenium), has shown anti-leukemic activity. We evaluated the cell cycle status and the phosphorylation/activation of proteins involved in signal transduction in t(4;11) and non-t(4;11) acute lymphoblastic leukemia (ALL) cell lines after treatment with parthenolide. The cells were treated with the vehicle or 10 μM parthenolide for 2, 4, 6 and 8 h. As shown by flow cytometric analysis, parthenolide induced growth arrest at the S to G2/M phase transition. Using multiplex technology and Western blotting, we showed that the treatment with parthenolide within 0 to 10 h induced the phosphorylation of stress signaling proteins, including the p38 mitogen-activated protein kinase, the c-Jun N-terminal kinase, c-Jun, the heat shock protein 27 and protein kinase B. These data show that parthenolide induces a stress response leading to cell death and provide further evidence suggesting that parthenolide could be useful as a novel therapeutic agent against high risk ALL with chromosomal translocation t(4;11).

Introduction

Parthenolide, a sesquiterpene lactone, is the principal bio-active component of the medicinal herb feverfew (Tanacetum parthenium) (1). Feverfew has been used in folk medicine to treat fever, migraines, inflammation, stomach ache, toothache, menstrual irregularities, and rheumatoid arthritis (2-5). Parthenolide has also shown anti-cancer activities (6). The potent anti-cancer activity of this substance is due in part to its ability to inhibit the transcription factor NF-κB, thereby reducing the survival potential of a number of cancer cells (6-8). Furthermore, the parthenolide-induced generation of reactive oxygen species (ROS) in cancer cells plays a key role in promoting apoptotic cell death (9,10).

The chromosomal translocation t(4;11)(q21;q23) is found in 60-85% of infants, 2% of children, and 3-6% of adults diagnosed with acute lymphoblastic leukemia (ALL) and the presence of this chromosomal abnormality is strongly associated with poor prognosis (11,12). This type of leukemia is deemed a high-risk subgroup of ALL and is highly resistant to conventional chemotherapeutics, necessitating further research to find potential novel therapeutic agents. We previously reported that parthenolide effectively induced apoptotic cell death in SEM and RS4;11 cell lines established from patients with ALL carrying the t(4;11) chromosomal translocation (13). Compared to the REH leukemia cells which have no translocation, parthenolide killed the t(4;11) ALL cells more rapidly at a lower concentration. Cell death in these leukemic cells was accompanied by increases in multiple ROS, including nitric oxide, superoxide anion and hypochlorite anion (13).

In the present study, we examined the early intracellular protein signaling events leading to parthenolide-induced apoptosis in these leukemia cells. Parthenolide treatment induced activation (phosphorylation) of several proteins involved in the stress response, including the heat shock protein 27 (HSP27), protein kinase B (Akt), c-Jun N-terminal kinase (JNK), c-Jun and the p38 mitogen-activated protein kinases (p38 MAPK). These data demonstrate part of the mechanism by which parthenolide induces cell death in t(4;11) and non-t(4;11) ALL cells, and provide further information suggesting that this phytochemical could be useful as a novel therapeutic agent against ALL.

Materials and methods

Cell lines and reagents. SEM and RS4;11 are established cell lines from patients diagnosed with high-risk pre-B cell ALL containing the chromosomal translocation t(4;11)(q21;q23)
Multiplex measurements of phosphoproteins. The phosphorylation status of the proteins Akt, ERK1/2, JNK, p38 MAPK, c-Jun, and HSP27 was assessed using the Bio-Plex Phosphoprotein Detection kit (Bio-Rad, Hercules, CA). The SEM, RS4;11 and REH cells were treated with 0.1% DMSO as the control or 10 μM parthenolide, and the cell lysates were prepared at 2, 4, 6, 8 and 10 h. Lysates were also prepared from untreated cells as a zero time-point. Cell lysates were prepared at 2, 4, 6, 8 and 10 h. Lysates were also prepared from untreated cells as a zero time-point. Cell lysates were prepared from 2.5x10^6 cells at each time-point with lysate concentrations for each lysate were measured using the Bio-Rad DC Protein Assay. Bovine γ-globulin was used as the standard for the protein measurements. Lysate samples and supplied lysate controls were analyzed in duplicate on a Bio-Plex multiplex flow cytometry instrument (Bio-Rad) following the phosphoprotein detection kit instructions except that 50 beads were acquired per bead region instead of 25. The data were expressed as the means of the median bead intensities normalized to the protein concentration in each well.

Western blot analysis of total and phosphoproteins. For further analysis of the protein levels of the total protein and phosphorylation status after DMSO or 10 μM parthenolide treatment, protein lysates were prepared by vortexing 1x10^6 cells per ml of lysis buffer containing 1% Triton X-100 (Sigma), 50 mM Tris-Cl, pH 8.0, 150 mM NaCl, and the following protease inhibitors: aprotinin, leupeptin, EDTA (Sigma) and Pefabloc SC (Roche Diagnostics). Protein concentrations were measured using the Bio-Rad DC Protein Assay. Equal amounts of protein (40 μg) were electrophoresed on 10% SDS-polyacrylamide gels under reducing conditions and electroblotted on to PVDF membranes (GE Healthcare, Piscataway, NJ). The blocking and staining of membranes were carried out using Tris-buffered saline containing 5% bovine serum albumin, Fraction V (Sigma) and 0.1% Tween-20 (Sigma). Rabbit polyclonal antibodies against phosphorylated and total Akt, p38 MAPK, JNK, c-Jun, phosphorylated HSP27 and mouse antibody against total HSP27, and mouse antibody against total HSP27, were purchased from Cell Signaling Technology (Danvers, MA) and used according to the manufacturer’s instructions. HRP-conjugated donkey anti-rabbit and sheep anti-mouse IgGs (GE Healthcare) were used as secondary antibodies at a dilution of 1:1000. The ECL Western blotting system (GE Healthcare) was used for the visualization of immunoreactive bands at the concentrations suggested by the manufacturer.

Statistical analysis. All the statistical analyses were performed with GraphPad software (GraphPad Software, Inc., San Diego, CA) and the data were displayed as arithmetic means ± SEM. For analysis of the cell cycle and Bio-Plex data, two-way analysis of variance (ANOVA) with Bonferroni post-hoc tests was used to determine the differences in the cell cycle profiles and in the relative levels of phosphoproteins over time between the DMSO- and parthenolide-treated cells. The confidence interval for significant differences was set at 95%.

Results

Parthenolide induces cell cycle arrest. In previous studies, we found that 10 μM parthenolide was a potent inducer of apoptosis in t(4;11) ALL-derived cell lines. In this study, we examined the early events leading to apoptosis after parthenolide treatment by first evaluating whether parthenolide influenced the cell cycle in these leukemic cells prior to the induction of apoptosis. The cells were treated with DMSO or 10 μM parthenolide and the cell cycle changes were measured at 2, 4, 6 and 8 h after treatment. Fig. 1 shows that the cells were arrested at the G0/G2/M transition of the cell cycle by parthenolide treatment in the SEM and REH cells within 4 h and in the RS4;11 cells within 8 h. This is evident by an accumulation of cells in the S phase and a reduction of cells in G2/M. At 8 h post-parthenolide treatment, the SEM cells were undergoing cell death and this was displayed by an accumulation of cells in the subG1 population (Fig. 2). An increase in cells in the G1 phase was observed at this time-point for SEM and this was possibly due to the progressive loss of 4N DNA resulting in a mixture of signals in the 2N G1 population. Therefore, this increase was not considered a parthenolide-induced G1 arrest. No subG1 population was detected for the other time-points for any cell line, other than the 8-h time-point for SEM.
Parthenolide treatment activates stress response proteins. We then analyzed signal transduction pathways in order to determine the early signaling events leading to parthenolide-induced apoptosis in leukemic cells. Multiplex technology was used to evaluate multiple proteins simultaneously from single samples. The activation of proteins involved in signal transduction was determined by measuring the phosphorylation status of each protein at 0, 2, 4, 6, 8 and 10 h post-treatment with parthenolide or DMSO. Several proteins directly involved in the cellular stress response leading to apoptosis were phosphorylated. The levels of phosphorylated p38 MAPK were increased in all 3 lines compared to the control cells and the differences between the treatment groups were significant at each time-point (P<0.05; Fig. 3A). The level of phosphorylated JNK was greatest in the SEM and RS4;11 cells (P<0.05; Fig. 3B). The differences in phosphorylated JNK between the treatment groups were significant in the REH cells, but the detectable levels remained low compared to the SEM and RS4;11 cells. Phosphorylated c-Jun levels were also elevated in the parthenolide-treated compared to the control cells for all 3 lines (P<0.05; Fig. 3C). Significant signals for phosphorylated p38MAPK, JNK and c-Jun were sustained throughout the 10-h time period after parthenolide treatment, indicating that the treatment with parthenolide maintained stress on the leukemia cells.

The proteins HSP27 and Akt are considered survival proteins and the activation of these proteins in response to parthenolide treatment, was also analyzed. An increase in phosphorylated HSP27 was observed in the SEM cells during the first 6 h of treatment with parthenolide, with a reduction in the phosphorylated form occurring within 8 h after treatment (P<0.05; Fig. 4A). RS4;11 showed the largest increase in the phosphorylation of HSP27 after the treatment with parthenolide and the phosphorylation was maintained for at least 10 h after treatment. It should be noted that even though the differences between the treatment groups was significant in the REH cells, the signal for phosphorylated HSP27 in these cells was exceedingly low compared to the signal in the SEM and RS4;11 cells, as indicated by the y-axis values. The phosphorylation status of Akt was also variable between the 3
Significant phosphorylation and activation of Akt occurred in the SEM and REH cells after the treatment with parthenolide compared to the control cells (P<0.05). However, no changes in the phosphorylation status of Akt was observed in the RS4;11 cells between the 2 treatment groups.

**Figure 3.** Stress proteins are phosphorylated after treatment with parthenolide. SEM, RS4;11 and REH cells were treated with DMSO (control) or 10 μM parthenolide for 2, 4, 6, 8 and 10 h. Cell lysates were prepared and run in duplicate on a Bio-Plex multiplex instrument. Lysates were analyzed for phosphorylated A) p38 MAPK, B) JNK and C) c-Jun. The data are expressed as the means of the median bead intensities normalized to the protein concentration in each well. MFI, mean fluorescent intensity. The asterisks represent the significant differences compared to the control cells for each time-point (P<0.05).

**Figure 4.** Protective proteins are phosphorylated after treatment with parthenolide. SEM, RS4;11 and REH cells were treated with DMSO (control) or 10 μM parthenolide for 2, 4, 6, 8 and 10 h. Cell lysates were prepared and run in duplicate on a Bio-Plex multiplex instrument. Lysates were analyzed for phosphorylated A) HSP27 and B) Akt. The data are expressed as the means of the median bead intensities normalized to the protein concentration in each well. MFI, mean fluorescent intensity. The asterisks represent the significant differences compared to the control cells for each time-point (P<0.05).
except for the phosphorylated p38 MAPK in the REH cells, with parthenolide. These data agree with the multiplex data, slightly in the SEM and RS4;11 lysates after the treatment phosphorylated Akt were increased in the REH cells, but only after the treatment with parthenolide. The levels of phosphorylated HSP27 (Ser78) was present in the lysates from the SEM and RS4;11 cells, but not in the REH cells. Phosphorylated Akt were increased in the REH cells, which were taken at the 4-h time-point based on the 10-h time-point except for HSP27 and Akt, which were from the 4-h time-point. For each protein, the upper panel represents the phosphorylated protein, and the bottom panel represents the total protein. For each cell line: (-) Untreated; (+) parthenolide-treated.

**Confirmation of phosphorylation status by Western blot analysis.** Western blot analysis was performed in order to confirm the phosphorylation status of the above-mentioned proteins and to compare the total proteins after DMSO or 10 μM parthenolide treatment (Fig. 5). Lysates represented the 10-h time-point except for HSP27 and Akt in the SEM cells, which were taken at the 4-h time-point based on the multiplex analyses. An increase in the phosphorylated p38 MAPK protein (Thr180/Tyr182) was detectable in all 3 cell lines, with the lowest signal observed in the REH cells. Two isoforms of JNK (46 and 54 kD) were observed and an increase in phosphorylated JNK (Thr183/Tyr185) was observed in the 3 lines after the treatment with parthenolide. Two isoforms of total c-Jun (43 and 48 kD) were expressed in the 3 lines and an increase in phosphorylated c-Jun (Ser63) was presented in the cells treated with parthenolide. Phosphorylated HSP27 (Ser78) was present in the lysates from the SEM and RS4;11 cells, but not in the REH cells after the treatment with parthenolide. The levels of phosphorylated Akt were increased in the REH cells, but only slightly in the SEM and RS4;11 lysates after the treatment with parthenolide. These data agree with the multiplex data, except for the phosphorylated p38 MAPK in the REH cells, where multiplex data showed a significant increase in phosphorylated protein similar to the signals obtained from the SEM and RS4;11 cells.

**Discussion**
These data show that treatment with parthenolide induces growth arrest and stress signaling responses in (t(4;11) ALL lines, as well as ALL cells without the chromosomal translocation. Parthenolide induced an arrest in the S to G2/M transition in all 3 cell lines within 8 h after treatment. Other studies have also reported a transient G2/M arrest in HL60 myeloid and Jurkat T-cell leukemia lines after treatment with parthenolide (16). The activation of p38 MAPK has been shown to induce G2/M arrest in response to DNA damage (17-19). The arrest of cells in G2/M by p38 MAPK was shown to occur by at least 2 mechanisms: i) By the p38 MAPK-induced activation of the tumor suppressor protein p53 leading to a p53-dependent G2/M arrest. The activation of p53 leads to the transcription of p21, the growth arrest and DNA damage 45a and 14-3-3 proteins resulting in the downstream association with and inactivation of the mitotic cyclin B/Cdc2 complex. ii) By phosphorylating and inactivating the Cdc25B phosphatase required to activate the cyclin B/Cdc2 complex so that cells can progress through mitosis (17). The phosphorylation and dephosphorylation of the cyclin B/Cdc2 protein complex regulate the transition of cells through mitosis (20,21). Specialized Cdc25 phosphatases are key players in the regulation of the phosphorylation and activation status of the cyclin B/Cdc2 complex (22,23). Although we did not test for DNA damage, the formation of high molecular weight fragments of ~700, 300 and 50 kbp correlates with the early chromatin alterations displayed in pre-apoptotic cells (24,25). In our previous studies, we showed that parthenolide induced the generation of significant levels of ROS in leukemia cells within the first 4 h of treatment (13), which can lead to damaged DNA and subsequent growth arrest (26). The activation of p38 MAPK by parthenolide in SEM, RS4;11 and REH cells could be a product of the parthenolide-induced generation of ROS in these cells.

The treatment of leukemic cells in our study resulted in the phosphorylation of JNK and c-Jun. The JNK signaling pathway plays a major role in apoptosis (27). JNK has been shown to translocate to the mitochondria and influence mitochondrial-mediated apoptosis (28,29). Parthenolide induces mitochondrial-mediated apoptosis in the leukemia cell lines (13), possibly through the action of activated JNK. JNK has also been shown to inactivate the anti-apoptotic proteins, Bcl-2 and Bcl-XL, and to enhance the activation of the pro-apoptotic proteins, Bad, Bim and Bax (29-33). In a previous study, we showed that REH cells were less sensitive to the induction of apoptosis by parthenolide than the SEM and RS4;11 cells (13). REH cells required 25 μM parthenolide in order to induce the equivalent level of death observed in the SEM and RS4;11 cells treated with 10 μM parthenolide. In the current study, the parthenolide-induced phosphorylation of JNK and c-Jun was reduced in the REH cells compared to that observed in the SEM and RS4;11 cells. These data suggest that the activation of the JNK signaling pathway is an important event for inducing the more rapid apoptotic death seen in the (t(4;11) ALL lines.
HSP27 is a member of the small heat shock protein family and has multiple functions (34). The activation of HSP27 is induced in the cells by many types of environmental stress including heat shock, inflammatory cytokines and oxidants, and plays a protective role (35). HSP27 has been shown to inhibit stress-induced apoptosis by binding to apoptogenic cytochrome c after release from the mitochondria and the interference with downstream caspase activation (36,37). HSP27 inhibits the activation of the pro-apoptotic protein Bax (38). HSP27 has also been shown to inhibit apoptosis by the direct interaction and activation of Akt (39). The phosphorylation and activation of HSP27 occurred within the first 2 h after the parthenolide treatment of SEM and RS4;11. The SEM cells had elevated levels of both phosphorylated HSP27 and Akt. However, the RS4;11 cells had increased levels of phosphorylated HSP27, but no activation of Akt above the control levels, and the REH cells showed low levels of phosphorylated HSP27, but significant levels of phosphorylated Akt. Furthermore, SEM and RS4;11 were more sensitive to parthenolide-induced apoptosis. Therefore, the importance of HSP27 and Akt activation as possible protective events in response to parthenolide treatment, is not clear.

The stimulation of conflicting pathways promoting and protecting from apoptosis provides a system for investigating the roles of these stress proteins in apoptotic and/or survival signaling. These data provide further evidence for the potential of parthenolide as a novel therapeutic and show at least part of the mechanism of parthenolide-induced apoptosis in ALL cells. Further evaluation in animal models is required in order to evaluate the bioavailability and efficacy of parthenolide against high-risk leukemia in vivo.

Acknowledgements

This study was funded by grants from the St. Baldrick’s Foundation to J.M.D. and the United States Department of Agriculture, CRIS project (no. 5306-51530-013-00D) to J.M.D. and the United States Department of Agriculture, CRIS project (no. 5306-51530-013-00D) to J.M.D. and the United States Department of Agriculture, CRIS project (no. 5306-51530-013-00D) to J.M.D.

References


